Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function

NCT04901299 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04901299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04901299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2023
Completion date
July 1, 2025
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

er positive breast cancer, her2-negative breast cancer, invasive breast cancer, metastatic breast cancer, pr-positive breast cancer, stage iv (metastatic) breast cancer